Medical Cannabis: a crucial step towards a French ecosystem
![](https://www.stanipharm.com/wp-content/uploads/2022/02/medical-cannabis-France-2022.png)
Pharmaceutical companies qualified to manufacture either active substances or medicines will now be able to produce cannabis-based medicines in France.
Developing a French “patient to seed” ecosystem to improve the therapeutic benefit of medical Cannabis
![](https://www.stanipharm.com/wp-content/uploads/2021/01/Feature-blog-image-Medicinal-Cannabis-StaniPharm-French-Ecosystem.png)
“Simply replacing the imported products currently specified for the pilot program with French-produced equivalents would be a missed opportunity and a disservice to patients”
Drug nanoparticles – a common approach to tackle the poor aqueous solubility of APIs
![](https://www.stanipharm.com/wp-content/uploads/2021/01/featured-image-nano.jpg)
Nanosizing drug particles brings key benefits for oral formulations of poorly soluble drugs such as Biopharmaceutics Classification System (BCS) Class II drugs.
8 supercritical companies inspired by Michel Perrut, founder of SEPAREX
![](https://www.stanipharm.com/wp-content/uploads/2021/01/LICOSEP-8-200-900-300.jpg)
SEPAREX, the gold standard in supercritical fluids, was founded in 1985 by Michel Perrut.
SEPAREX was also a pioneering business incubator, far ahead of its time, contributing to the birth of 8 companies.